Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available.
IRLAB Therapeutics AB announced the last day for trading subscription rights in their rights issue, which aims to issue new shares of series A with preferential rights for existing shareholders. The rights issue, if fully subscribed, is expected to raise approximately SEK 136 million before costs, with 85% of the issue secured by subscription and guarantee undertakings. Shareholders who do not participate may face dilution but can sell their rights to mitigate financial impact.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a company operating in the biotechnology industry, focusing on the development of novel treatments for neurological diseases. Their primary products include innovative drug candidates aimed at addressing disorders such as Parkinson’s disease, with a market focus on improving patient outcomes in the field of neurology.
YTD Price Performance: -64.53%
Average Trading Volume: 62,997
Current Market Cap: SEK326.8M
For a thorough assessment of IRLAB.A stock, go to TipRanks’ Stock Analysis page.